Matches in SemOpenAlex for { <https://semopenalex.org/work/W183785196> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- W183785196 abstract "illions of people have already benefited from medicines and vaccines developed through biotechnology, and a new report offers hope that in the future many more will benefit. The report found 418 biotechnology medicines in development for more than 100 diseases. These include 210 medicines for cancer, 50 for infectious diseases, 44 for autoimmune diseases, and 22 for AIDS/HIV and related conditions. These potential medicines, all of which are either in human clinical trials or under review by the Food and Drug Administration, will add to the list of 125 biotechnology medicines already approved and available to patients. Approved biotechnology medicines already treat or help prevent heart attacks, stroke, multiple sclerosis, leukemia, hepatitis, rheumatoid arthritis, breast cancer, diabetes, congestive heart failure, lymphoma, kidney cancer, cystic fibrosis, and other diseases. These medicines rely on many cutting-edge technologies. For example, most early biotechnology medicines were protein drugs, produced by splicing genes into bacteria. They include recombinant insulin, human growth hormone, clotting factor for hemophilia patients, and erythropoietin to stimulate the production of red blood cells in kidney dialysis and cancer patients. Another type of biotechnology medicine, the monoclonal antibody, is a laboratory-made version of the naturally occurring protein that binds to and neutralizes foreign invaders. The first monoclonal antibody that inhibits angiogenesis (the formation of new blood vessels) was approved for the treatment of metastatic colorectal cancer in 2004. Interferons, proteins that interfere with the ability of a cell to reproduce, are the basis of existing medicines for osteoporosis, chronic granulomatous disease, genital warts, multiple sclerosis, hairy cell leukemia and other diseases. Antisense drugs are medicines that interfere with the communication process that tells a cell to produce an unwanted protein. The first antisense drug, for the treatment of cytomegalovirus retinitis in AIDS patients, was approved in 1998." @default.
- W183785196 created "2016-06-24" @default.
- W183785196 creator A5033318817 @default.
- W183785196 date "2006-01-01" @default.
- W183785196 modified "2023-09-26" @default.
- W183785196 title "418 Biotechnology Medicines in Testing Promise to Bolster the Arsenal Against Disease" @default.
- W183785196 hasPublicationYear "2006" @default.
- W183785196 type Work @default.
- W183785196 sameAs 183785196 @default.
- W183785196 citedByCount "2" @default.
- W183785196 crossrefType "journal-article" @default.
- W183785196 hasAuthorship W183785196A5033318817 @default.
- W183785196 hasConcept C121608353 @default.
- W183785196 hasConcept C126322002 @default.
- W183785196 hasConcept C150903083 @default.
- W183785196 hasConcept C203014093 @default.
- W183785196 hasConcept C2777575956 @default.
- W183785196 hasConcept C2779134260 @default.
- W183785196 hasConcept C71924100 @default.
- W183785196 hasConcept C86803240 @default.
- W183785196 hasConceptScore W183785196C121608353 @default.
- W183785196 hasConceptScore W183785196C126322002 @default.
- W183785196 hasConceptScore W183785196C150903083 @default.
- W183785196 hasConceptScore W183785196C203014093 @default.
- W183785196 hasConceptScore W183785196C2777575956 @default.
- W183785196 hasConceptScore W183785196C2779134260 @default.
- W183785196 hasConceptScore W183785196C71924100 @default.
- W183785196 hasConceptScore W183785196C86803240 @default.
- W183785196 hasLocation W1837851961 @default.
- W183785196 hasOpenAccess W183785196 @default.
- W183785196 hasPrimaryLocation W1837851961 @default.
- W183785196 hasRelatedWork W1758502430 @default.
- W183785196 hasRelatedWork W1940810331 @default.
- W183785196 hasRelatedWork W1971633040 @default.
- W183785196 hasRelatedWork W1995176122 @default.
- W183785196 hasRelatedWork W2013093849 @default.
- W183785196 hasRelatedWork W2030668858 @default.
- W183785196 hasRelatedWork W2051266349 @default.
- W183785196 hasRelatedWork W2147828209 @default.
- W183785196 hasRelatedWork W2318411520 @default.
- W183785196 hasRelatedWork W2418186628 @default.
- W183785196 hasRelatedWork W2418631484 @default.
- W183785196 hasRelatedWork W2468344268 @default.
- W183785196 hasRelatedWork W2469400279 @default.
- W183785196 hasRelatedWork W2749376811 @default.
- W183785196 hasRelatedWork W2809593557 @default.
- W183785196 hasRelatedWork W2883863660 @default.
- W183785196 hasRelatedWork W2894980778 @default.
- W183785196 hasRelatedWork W2982463967 @default.
- W183785196 hasRelatedWork W87537534 @default.
- W183785196 hasRelatedWork W2184037613 @default.
- W183785196 isParatext "false" @default.
- W183785196 isRetracted "false" @default.
- W183785196 magId "183785196" @default.
- W183785196 workType "article" @default.